BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program

News   Aug 14, 2009

 
BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program
 
 
 

RELATED ARTICLES

Concept Life Sciences appoints New Group Programme Manager and US Head of Sales

News

Key leadership appointments support integration of the Group and expansion in the US market.

READ MORE

Brian Berridge Set to Manage National Toxicology Program

News

The National Toxicology Program (NTP) has named Brian Berridge, D.V.M., Ph.D., as its new Associate Director. Berridge, formerly of GlaxoSmithKline, will oversee day-to-day operations as NTP coordinates toxicology research and testing across nine different federal agencies.

READ MORE

Safety and Efficacy of MERS Treatment Confirmed in Phase I Trial

News

An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE